MS Therapy May Work in Part by Lowering EBV Immune Response Study finds that anti-CD20 drugs lower viral T-cell levels in MS patients Anti-CD20 therapies may be highly effective in multiple sclerosis (MS) partly because they reduce the immune system’s ongoing response to the Epstein-Barr virus, a risk factor for MS, according to a study. (Photo from iStock) Anti-CD20 therapies effectively treat MS partly by reducing the immune system’s ongoing response to the Epstein-Barr virus, a study reports. Patients on these treatments show significantly fewer Epstein-Barr virus-specific T-cells compared to…
Read MoreMS Therapy May Work in Part by Lowering EBV Immune Response
